Advancing Osteoarthritis Treatment with
CAL-05CR: A New Era of Pain Relief

Sustained-Release Innovation: Targeting Osteoarthritis at the Root for Long-Lasting Relief Without the Complications.

At Calosyn Pharma, we are transforming the landscape of osteoarthritis treatments with our innovative lead product, CAL-05CR. Designed to address the limitations of current therapies, CAL-05CR offers sustained, local pain relief while minimizing the side effects often associated with traditional treatment options.

CAL-05CR: A Game-Changer in Osteoarthritis Therapy

CAL-05CR is an injectable, intra-articular treatment specifically developed for patients suffering from moderate to severe osteoarthritis pain. It represents a breakthrough in osteoarthritis management by utilizing two critical components: verapamil and a well studied biodegradable polymer for delivery.

How It Works: Targeting the Root Cause

Unlike conventional treatments that merely address symptoms, CAL-05CR goes beyond pain relief to target the underlying causes of osteoarthritis. Verapamil works by regulating calcium ion channels, which are implicated in the degenerative processes of osteoarthritis. By interfering with these channels, CAL-05CR reduces the release of harmful enzymes, ultimately lowering inflammation and preserving joint function.

Sustained-Release Technology for Long-Lasting Relief

What sets CAL-05CR apart is its sustained-release mechanism. By embedding verapamil in microspheres, CAL-05CR provides continuous therapeutic concentrations directly within the joint, ensuring consistent pain relief over an extended period, and eliminating the need for frequent injections.

WHY CAL-05CR?

  1. Long-Lasting Pain Relief: CAL-05CR provides months of pain relief from a single injection, reducing the need for frequent medical interventions.

  2. Minimized Side Effects: Unlike systemic osteoarthritis treatments, CAL-05CR delivers its effects locally, significantly lowering the risk of side effects.

  3. Root Cause Focus: By targeting calcium ion channels, CAL-05CR addresses osteoarthritis at its source, offering more than just symptom relief.

  4. Proven Efficacy: Extensive pre-clinical and clinical studies support the efficacy of verapamil in reducing osteoarthritis-related pain, with CAL-05CR showing promise as a superior treatment option.

Designed with Patients in Mind

At Calosyn Pharma, patient well-being is our top priority. That’s why CAL-05CR is designed to not only provide relief but also to improve the quality of life for those living with osteoarthritis. With fewer side effects, fewer injections, and longer-lasting results, CAL-05CR offers a more patient-friendly solution for managing osteoarthritis.

The Future of Osteoarthritis Treatment

Calosyn Pharma is committed to advancing osteoarthritis therapies that offer real solutions. CAL-05CR represents the future of osteoarthritis treatment—one that prioritizes sustained relief, fewer complications, and a focus on the root causes of the disease. Our ongoing research and commitment to innovation continue to drive us towards creating better outcomes for osteoarthritis patients worldwide.